Experimental Therapeutics Program (Project-003)

实验治疗计划（Project-003）

基本信息

批准号：
9149894
负责人：
John M Hoffman
金额：
$ 7.79万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9149894
关键词：
Abbreviations Acceleration Address Antineoplastic Agents Area Basic Science Biology Cancer Center Cancer Center Support Grant Clinic Clinical Clinical Research Clinical Treatment Clinical Trials Clinical Trials Cooperative Group Collaborations Conduct Clinical Trials Cooperative Group Program Development Disease Drug Delivery Systems Drug Design Drug usage Ensure Evaluation Fostering Funding Generations Genetic Goals Home environment Human Image Institutes Investigational Therapies Laboratories Lead Leadership Liquid substance Malignant Neoplasms Mission Modeling Multi-Institutional Clinical Trial National Cancer Institute National Clinical Trials Network New Agents Paper Patient Care Patients Peer Review Performance Pharmaceutical Preparations Pharmacy facility Population Publishing Research Research Personnel Resources Role Science Scientist Source Techniques Therapeutic Therapeutic Clinical Trial Therapeutic Uses Toxic effect Translating Translational Research Translations Treatment Efficacy Treatment-Related Cancer United States United States National Institutes of Health Universities Utah Work abstracting acronyms assay development base bench to bedside cancer cell cancer therapy cancer type clinical care college computational chemistry cost design drug development drug discovery experience image guided improved in vivo Model instructor interdisciplinary collaboration interest medical schools meetings member mid-career faculty multidisciplinary novel novel strategies novel therapeutics patient oriented research pre-clinical professor programs screening targeted delivery targeted treatment

项目摘要

EXPERIMENTAL THERAPEUTICS PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program of Huntsman Cancer Institute (HCI) is organized to facilitate transdisciplinary collaboration and to accelerate the progress of patient-oriented research to clinical translation and care of patients with cancer. The Program is organized into two main research themes: Drug Discovery/Drug Delivery and Clinical Research. Program members work to discover new agents that can be developed into drugs used to target cancer cells, develop second-generation polymeric carriers of anticancer drugs, design macromolecular targeted therapeutics with selective inhibitory effects on various types of malignancy, and develop drug-free macromolecular therapeutic constructs to increase efficacy of currently used therapeutics. Program members also ensure the execution of clinical research at HCI and the translation of important Cancer Center discoveries to human applications. Program members are also active in the leadership and conduct of clinical trials, including investigator-initiated trials. This clinical research focus aligns with the goals of NCI to develop and conduct state-of-the-art cancer treatment and advanced imaging multi- institutional clinical trials to evaluate new cancer therapies and related clinical approaches across a broad range of populations and cancer types. Program members are engaged in the effort to transform the previous NCI Clinical Trials Cooperative Group Program into a consolidated and integrated National Clinical Trials Network (NCTN), by providing clinical trials leadership and access to vitally important accruals among patients in the Intermountain West. The goals of the program are to: 1) provide new approaches to individualized cancer treatment as well as the most up-to-date clinical treatments via investigator-initiated therapeutic, imaging, and imaging-guided clinical trials; 2) foster bidirectional translation of discoveries between the laboratory and the clinic through collaborations and scientific synergy among ET program members, other program members, and HCI practicing clinicians; 3) develop novel therapies to meet unmet clinical needs in cancer through collaboration and interaction with the HCI multidisciplinary disease groups and disease-oriented research teams. The 39 ET Program members are drawn from 11 different University of Utah departments in the School of Medicine and Colleges of Pharmacy and Science. The Program includes 24 professors, seven associate professors, seven assistant professors, and one instructor, with 11 PhDs, 22 MDs, and six MD, PhDs. Funding includes $14.8M in 2013 total costs (NCI: 28%, other NIH: 20%, other peer-reviewed sources: 15%). From 2009–2013, ET members published 550 peer-reviewed papers, of which 28% involved collaboration with other Cancer Center members and 66% involved external partnerships.

实验治疗计划抽象的亨斯曼癌症研究所 (HCI) 的实验治疗 (ET) 计划旨在促进跨学科合作，加速以患者为中心的研究向临床转化的进展该计划分为两个主要研究主题：药物。发现/药物输送和临床研究计划成员致力于发现可用于的新药物。开发成针对癌细胞的药物，开发第二代抗癌高分子载体药物，设计对多种类型具有选择性抑制作用的大分子靶向治疗药物恶性肿瘤，并开发无药大分子治疗结构以提高目前的疗效计划成员还确保 HCI 临床研究的执行和翻译。癌症中心的重要发现对人类的应用也很活跃。临床试验的领导和实施，包括研究者发起的试验，这一临床研究重点是一致的。 NCI 的目标是开发和实施最先进的癌症治疗和先进的成像多机构临床试验，以评估新的癌症疗法和广泛的相关临床方法计划成员致力于改变以前的人群和癌症类型。 NCI 临床试验合作小组计划整合为统一的国家临床试验网络 (NCTN)，通过提供临床试验领导力并获得患者中至关重要的应计成果在西山间。该计划的目标是：1）提供个体化癌症治疗的新方法以及通过研究者发起的治疗、影像学和影像引导提供最新的临床治疗临床试验；2）通过以下方式促进实验室和临床之间发现的双向转化： ET 计划成员、其他计划成员和 HCI 之间的合作和科学协同 3）通过合作开发新疗法来满足癌症中未满足的临床需求以及与 HCI 多学科疾病组和疾病导向研究团队的互动。 39名ET项目成员来自犹他大学学院的11个不同院系该项目包括 24 名教授、7 名副教授。现有教授 7 名，助理教授 7 名，讲师 1 名，博士 11 名，医学博士 22 名，医学博士、博士 6 名。包括 2013 年总成本 1,480 万美元（NCI：28%，其他 NIH：20%，其他同行评审来源：15%）。 2009-2013年，ET成员发表了550篇同行评审论文，其中28%涉及与其他组织的合作癌症中心成员中有 66% 涉及外部合作伙伴关系。